Monitoring of the liver function test (particularly the ALT) should occur at the beginning of the treatment, then every month for 12 months, and then every three months.

In the case of renal impairment, no adjustment in the dose is necessary.

If rosiglitazone is being co-administrated with sulfonylureas, dosage adjustments and patient monitoring are recommended to avoid hypoglycemic incidents.